Cita APA (7a ed.)

I, A., A, L., A, T., & E, B. (2019). Cardiovascular Risk Reduction in Type 2 Diabetes: Therapeutic Potential of Dapagliflozin. Dove Medical Press.

Cita Chicago Style (17a ed.)

I, Avgerinos, Liakos A, Tsapas A, y Bekiari E. Cardiovascular Risk Reduction in Type 2 Diabetes: Therapeutic Potential of Dapagliflozin. Dove Medical Press, 2019.

Cita MLA (8a ed.)

I, Avgerinos, et al. Cardiovascular Risk Reduction in Type 2 Diabetes: Therapeutic Potential of Dapagliflozin. Dove Medical Press, 2019.